Key facts
- VarmX’s last known valuation is $505.0M (Sep 2025).
- It has raised $102.5M; the latest was Merger/Acquisition ($505.0M) in Sep 2025.
- Notable investors include EQT Life Sciences, InnovationQuarter, MaasInvest, BioGeneration Ventures, CSL — 13 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for VarmX
- ·The full record, as it builds
Funding rounds
No funding rounds for VarmX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VarmX
Manufacturer of therapeutic drugs designed to restore blood clotting in patients experiencing bleeding events. The company offers drugs based on modified recombinant human coagulation factors effective in the presence of direct factor anticoagulants, enabling physicians and healthcare providers to manage urgent bleeding and surgical care safely.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2016
- Employees
- 25
- Website
- varmx.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
VarmX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VarmX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VarmX in its N-PORT filings yet. We sweep new filings monthly.